Currently with about 900 SKUs MAAs authorizations under submissions and more than 50 ANDA filings in the USA under way.
The portfolio includes all major therapeutic areas such as cardiovascular, CNS, Oncology, Respiratory and Biosimilars.
Leveraging local know-how and vast portfolio, Alvogen is growing its presence and capturing market share with multiple new product launches in all key markets.